Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A multicentre study to assess safety and efficacy of psilocybin in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)

To see complete record on, please visit this link

Id: 2020-001348-25

Organisation Name: COMPASS Pathways, Ltd

Start Date: 2020-07-08

Completion Date: Ongoing

Brief Summary: The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).

Country: United Kingdom

Total execution time in seconds: 0.073364019393921